Brief Article
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 7, 2014; 20(17): 4994-4999
Published online May 7, 2014. doi: 10.3748/wjg.v20.i17.4994
Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma
Frank Serge Lehmann, Francesca Trapani, Ida Fueglistaler, Luigi Maria Terracciano, Markus von Flüe, Gieri Cathomas, Andreas Zettl, Pascal Benkert, Daniel Oertli, Christoph Beglinger
Frank Serge Lehmann, Christoph Beglinger, Division of Gastroenterology and Hepatology, University Hospital, 4031 Basel, Switzerland
Francesca Trapani, Luigi Maria Terracciano, Institute of Pathology, University Hospital, 4003 Basel, Switzerland
Ida Fueglistaler, Markus von Flüe, St. Clara Hospital, 4016 Basel, Switzerland
Gieri Cathomas, Institute of Pathology, University Hospital, 4410 Liestal, Switzerland
Andreas Zettl, Institute of Pathology, Viollier AG, 4002 Basel, Switzerland
Pascal Benkert, Clinical Trial Unit, University Hospital, 4031 Basel, Switzerland
Daniel Oertli, Department of Surgery, University Hospital, 4031 Basel, Switzerland
Author contributions: All authors had contributed significantly, were in agreement with the content of the manuscript, read and approved the final manuscript. Lehmann FS, Terracciano LM and Beglinger C participated in study conception and design, acquisition, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content, and having full access to all of the data in the study and taking responsibility for the integrity of the data and the accuracy of the data analysis; Benkert P was involved in the study design and performed the statistical analysis; Trapani F performed all histopathological studies; Fueglistaler I, von Flüe M, Cathomas G, Zettl A and Oertli D participated in acquisition of data and revised the manuscript for intellectual content.
Supported by Unrestricted research grants to Dr. Lehmann FS by the Freiwillige Akademische Gesellschaft (Basel, Switzerland); and the Pfizer AG, Viollier Laboratories AG, Switzerland performed the fecal calprotectin assays
Correspondence to: Frank Serge Lehmann, MD, Division of Gastroenterology and Hepatology, University Hospital, Petersgraben 4, 4031 Basel, Switzerland. fslehmann@hin.ch
Telephone: +41-61-4210232 Fax: +41-61-4210274
Received: May 27, 2013
Revised: September 4, 2013
Accepted: September 16, 2013
Published online: May 7, 2014
Processing time: 344 Days and 16.6 Hours
Core Tip

Core tip: Colorectal cancer (CRC) patients have a significant increase of fecal calprotectin release. The mechanisms for this observation are unclear. In our study, we examined the calprotectin release before and after operation of 46 CRC patients. This is the first study that assessed the correlation of calprotectin with both tumor as well as histopathological parameters. Our study contains the following new information: (1) the release of calprotectin is exclusively correlated to the T-stage, but to no histopathological parameters; and (2) except the T-stage, all other tumor characteristics assessed by the seventh edition of the tumor node metastasis classification are not correlated.